Continuous vs. intermittent dosing of an antibiotic in ICU patients
Part of Infections clinical trials.
This trial tests two ways of giving the antibiotic ceftazidime/avibactam (a powerful drug for resistant bacteria) to critically ill patients in the ICU. The goal is to see if a continuous infusion works better than standard timed doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 85 years old.
- You are in the intensive care unit (ICU) with a severe infection.
- A lab test shows you have a specific resistant bacteria (OXA-48 Klebsiella or Pseudomonas).
- Your doctor has decided you need ceftazidime/avibactam.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
This trial tests if adjusting ceftazidime (a powerful antibiotic) early on helps treat serious infections better in intensive care patients. You may qualify if you are in the ICU and your doctor is considering starting this antibiotic.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests whether giving a certain type of antibiotic (beta-lactam) continuously or intermittently works better for patients in the intensive care unit with pneumonia or a urinary tract infection and signs of sepsis. Sepsis is a serious response to an infection, so better antibiotic delivery could improve outcomes.
Hear when a new Severe Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.